15 results
Hydroxychloroquine Serum Measurement in SLE
 • Terminal elimination half-life = 40 days ([HCQI reflects long-term intake)
Hydroxychloroquine ... • Special cases ... Lupusreference #Hydroxychloroquine ... Measurement #SLE #rheumatology ... pharmacology #levels #lupus
Systemic Lupus Erythematosus - Summary
Antinuclear (ANA) - 95% - Initial screening test
Anti-dsDNA - 50%
 • Associated
Systemic Lupus Erythematosus ... severe disease Treatment ... Mild disease- Hydroxychloroquine ... #Systemic #Lupus ... Summary #diagnosis #rheumatology
Rapidly Progressive Glomerulonephritis (RPGN)
RPGN has three primary pathophysiologic causes differentiated by immunofluorescence

Immune Complex Mediated (granular staining):
pathophysiologic causes ... Complement: Post-strep GN ... , Lupus Nephritis ... diagnosis #algorithm #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
constitutional symptoms • Treatment ... Discontinuation of causal ... drug +++, Hydroxychloroquine ... life-threatening • Treatment ... comparison #table #rheumatology
Hydroxychloroquine - Risks and Benefits in Lupus
Benefits:
↓ Disease activity, ↓ Flare, ↓ Damage, ↓ Corticosteroid dose,
Hydroxychloroquine ... and Benefits in Lupus ... Lupusreference #Hydroxychloroquine ... Risks #Benefits #Lupus ... #sideeffects #rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Manifestations of Systemic Lupus ... autoantibodies that will cause ... Puncture, EEG Treatment ... CNS #neurology #rheumatology ... diagnosis #management #treatment
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... , oral ulcers, Lupus ... Positive in 60-80% of cases ... life-threatening • Treatment ... Management #Summary #rheumatology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
: ARDS Berlin Criteria ... without other cause ... : 33% • Treatment ... : No • Treatment ... Transfusion #Reactions #hematology
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
SJIA], systemic lupus ... Histopathologic criteria ... Treatment: • Corticosteroids ... Diagnosis #Management #Hematology ... #Rheumatology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
constitutional symptoms • Treatment ... Discontinuation of causal ... drug +++, Hydroxychloroquine ... #DIL #rheumatology ... #diagnosis #treatment